PCN16 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE BEVACIZUMAB (BEV) + LOWER-DOSE INTERFERON-ALPHA2A IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, AND UNITED KINGDOM
作者
G. H. J. Mickisch,Bernard J. Escudier,M. E. Gore,Stefan Walzer,MJ Nuijten
出处
期刊:Value in Health [Elsevier BV] 日期:2009-05-01卷期号:12 (3): A38-A39被引量:1